Dow Pharmaceutical Sciences

Quick facts

Phase 3 pipeline

• IDP-108 · Diabetes
  IDP-108 is a small molecule that targets the SGLT2 receptor.
• IDP-110 · Diabetes
  IDP-110 is a small molecule that targets the SGLT2 receptor.

Phase 2 pipeline

• High Strength IDP-107
• High Strength IDP-108
• High Strength IDP-108 under occlusion
• IDP-115
• Low Strength IDP-107
• Low Strength IDP-108

Phase 1 pipeline

• IDP-118 High Strength
• IDP-118 Low Strength

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dow Pharmaceutical Sciences portfolio CI brief
• Dow Pharmaceutical Sciences pipeline updates RSS